CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025
CervoMed (NASDAQ: CRVO), a clinical stage company specializing in age-related neurologic disorders, will present late-breaking research at the Alzheimer's Association® International Congress (AAIC) 2025 in Toronto from July 27-31, 2025.
The company will showcase results from their RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) through two presentations: an in-person poster discussing effects on clinical progression in DLB patients without Alzheimer's disease co-pathology, and a virtual presentation examining the impact of AD co-pathology on treatment response.
CervoMed (NASDAQ: CRVO), un'azienda in fase clinica specializzata nei disturbi neurologici legati all'età, presenterà ricerche di grande rilievo al Congresso Internazionale dell'Alzheimer® (AAIC) 2025 che si terrà a Toronto dal 27 al 31 luglio 2025.
L'azienda mostrerà i risultati del loro studio RewinD-LB di fase 2b sul neflamapimod nella demenza con corpi di Lewy (DLB) attraverso due presentazioni: un poster in presenza che discuterà gli effetti sulla progressione clinica nei pazienti con DLB senza co-patologia di Alzheimer, e una presentazione virtuale che analizzerà l'impatto della co-patologia di Alzheimer sulla risposta al trattamento.
CervoMed (NASDAQ: CRVO), una empresa en etapa clínica especializada en trastornos neurológicos relacionados con la edad, presentará investigaciones de última hora en el Congreso Internacional de la Asociación de Alzheimer® (AAIC) 2025 en Toronto del 27 al 31 de julio de 2025.
La compañía mostrará resultados de su estudio RewinD-LB Fase 2b sobre neflamapimod en demencia con cuerpos de Lewy (DLB) a través de dos presentaciones: un póster presencial que discutirá los efectos en la progresión clínica en pacientes con DLB sin co-patología de Alzheimer, y una presentación virtual que examinará el impacto de la co-patología de Alzheimer en la respuesta al tratamiento.
CervoMed (NASDAQ: CRVO)는 연령 관련 신경 장애를 전문으로 하는 임상 단계 회사로, 2025년 7월 27일부터 31일까지 토론토에서 열리는 알츠하이머 협회 국제 학술대회(AAIC) 2025에서 최신 연구를 발표할 예정입니다.
회사는 루이체 치매(DLB)에서 네플라마피모드의 효과를 평가한 RewinD-LB 2b상 연구 결과를 두 가지 발표를 통해 선보입니다: 알츠하이머 병 병리 동반이 없는 DLB 환자의 임상 진행에 대한 효과를 다룬 현장 포스터 발표와, 알츠하이머 병 병리 동반이 치료 반응에 미치는 영향을 분석한 온라인 발표입니다.
CervoMed (NASDAQ : CRVO), une entreprise en phase clinique spécialisée dans les troubles neurologiques liés à l'âge, présentera des recherches de dernière minute au Congrès International de l'Association Alzheimer® (AAIC) 2025 à Toronto, du 27 au 31 juillet 2025.
L'entreprise mettra en avant les résultats de son étude RewinD-LB de phase 2b sur le néflamapimod dans la démence à corps de Lewy (DLB) à travers deux présentations : un poster en présentiel abordant les effets sur la progression clinique chez les patients DLB sans co-pathologie Alzheimer, et une présentation virtuelle examinant l'impact de la co-pathologie Alzheimer sur la réponse au traitement.
CervoMed (NASDAQ: CRVO), ein klinisch tätiges Unternehmen, das sich auf altersbedingte neurologische Erkrankungen spezialisiert, wird auf dem Alzheimer's Association® International Congress (AAIC) 2025 in Toronto vom 27. bis 31. Juli 2025 aktuelle Forschungsergebnisse präsentieren.
Das Unternehmen wird Ergebnisse seiner RewinD-LB Phase-2b-Studie zu Neflamapidom bei Demenz mit Lewy-Körperchen (DLB) in zwei Präsentationen vorstellen: ein persönliches Poster, das die Auswirkungen auf den klinischen Verlauf bei DLB-Patienten ohne Alzheimer-Ko-Pathologie diskutiert, sowie eine virtuelle Präsentation, die den Einfluss der Alzheimer-Ko-Pathologie auf die Behandlungsreaktion untersucht.
- None.
- None.
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person poster presentations at Alzheimer’s Association® International Congress (AAIC) 2025, being held on July 27 – 31, 2025 in Toronto, Canada. The Company will be presenting the results, including new results, from the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).
Details of the AAIC Developing Topics presentations are as follow:
Poster Title: Effects of neflamapimod (p38α kinase inhibitor) on clinical progression in patients with dementia with Lewy bodies (DLB) without Alzheimer’s disease (AD) Co-Pathology
Format: In-person Poster
Session Name: Developing Topics: Drug Development
Poster Number: #108769
Date and Time: Sunday, July 27, 2025 from 7:30 AM – 4:15 PM EDT
Poster Title: Impact of AD Co-Pathology on Response to Neflamapimod (p38α Kinase Inhibitor) in Patients with Dementia with Lewy Bodies
Format: Virtual Presentation
Session Name: Developing Topics
Poster Number: #108885
The posters will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/ following the presentation.
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
When and where will CervoMed (CRVO) present at AAIC 2025?
What will CervoMed (CRVO) present at AAIC 2025?
Where can investors access CervoMed's AAIC 2025 presentations?
What is the focus of CervoMed's two AAIC 2025 presentations?
